Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2000

View Archived Issues

U.S. and U.K. authorities sanction Glaxo Wellcome/SmithKline Beecham merger

Repligen licenses two patent applications from UCSD related to uses of uridine

Vivus granted third PDE inhibitor patent

Collaboration announced by Maxygen and Integrated Genomics

Questcor arranges Asian marketing agreement for metoclopramide nasal spray

Pierre Fabre describes bacterial cell wall protein with potential as cancer immunotherapy

Exclusive rights to nucleoside analogue acquired from SRI by Gilead

Commencement of phase I trial of IL-1 Trap for rheumatoid arthritis announced by Regeneron

Trial with nasal calcitonin concludes successfully

Positive allosteric modulators of GABA-A receptor designed and evaluated by European group

Nucleoside analogue MIV-210 enters phase I for HBV treatment

Celltech completes acquisition of Cistron

Immunomedics licenses humanized antibody for NHL to Amgen

Aldose reductase inhibitor developed in Japan submitted for regulatory review

Kyowa Hakko discusses work leading to development of therapeutically active 5-HT4 agonists

SD/01 is equally effective and safe as once-daily filgrastim over multiple cycles of chemotherapy

Dolastatin 10 has no significant efficacy in advanced breast cancer

Results from ongoing phase II trial of 9-NC in metastatic breast cancer reported in San Antonio

Faslodex highlighted at Breast Cancer Symposium as a novel approach to postmenopausal breast cancer

GABA analogues reported to modulate substance P

New use claimed by Sanofi-Synthelabo for succinic acid derivatives

Tetralone and thienylcyclohexanone derivatives selectively bind to GABA-A alpha5 subunit

Protein farnesyltransferase inhibitors useful for cancer therapy patented by BMS

New 4-arylpiperidine derivatives for the treatment of pruritus

Pfizer presents new mu-selective opioid receptor ligands and use thereof

Combined 5-HT1A/5-HT2/D2 receptor agonists designed at FAES

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...